Medarex Inc and Trillium Therapeutics Inc have collaborated for the development of fully human antibody therapeutics. Medarex plans to use its UltiMAb Human Antibody Development System(SM) to generate antibodies to disease targets identified by TTI.

Under the agreement, the two companies expect to share equally the cost and responsibility of the development of antibody products. In addition, the two companies plan to jointly commercialize and share equally future revenues arising from any antibody products resulting from this collaboration.

"This collaboration with Medarex, a leader in the field of monoclonal antibody therapeutics, is a testament to the high quality of TTI's science," stated Niclas Stiernholm, Chief Executive Officer of TTI. "Moreover, it brings us an experienced antibody development partner with a broad global industry network, which is invaluable to a young company like TTI."

"We are pleased to ally with TTI. We believe TTI's expertise in the area of immune-mediated disorders nicely complements Medarex's development capabilities. TTI has provided a promising target to kick-off this collaboration, and I am hopeful that the alliance will be fruitful," said Donald L. Drakeman, President and CEO of Medarex.